Home / Resources / Early Clinical resources

早期临床

精选资源

Model smarter, not harder: How Phoenix Cloud puts the science back at the center of modeling

博客

Upcoming early clinical webinars

网络研讨会

Unlock the Power of SEND Data: From FDA Compliance to Global Regulatory Readiness for Preclinical data [Korean Webinar]

2026 年 8 月 20 日 – 3:00 pm – 4:00 pm, Korea time

网络研讨会

Explore Smarter, Faster PK/PD with Phoenix

2026 年 8 月 25 日 – 10-11 AM ET/CET/JST

网络研讨会

Subcutaneous absorption model

2026 年 9 月 9 日 – 10:00 -10:45 AM ET

Latest early clinical blogs

All Early clinical - Blog

Blog

降低药物开发风险：早期开发中的关键化学、制造和控制（CMC）及基于生理的药代动力学（PBPK）方法

在以下活动中与我们的专家会面

现场活动

Simcyp 专题研讨会：DDI（复杂药物相互作用的预测与评估）日本

2026 年 8 月 3 - 4 日

现场活动

Simcyp 线下研讨会：PBPK 建模在生物药剂学中的应用 — 日本

2026 年 8 月 5 - 6 日

现场活动

Phoenix Pharmacometrics Day – Korea

2026 年 9 月 1 日

All early clinical resources

Important drug development questions that model-based meta-analysis answers

Certara Services, Clinical Pharmacology, Drug Development Support, Model Informed Drug Development, Modeling & Simulation - MBMA, Blog

Unlock the Power of SEND Data: From FDA Compliance to Global Regulatory Readiness for Preclinical data [Korean Webinar]

Certara Products - Pinnacle 21, Certara Products - SEND Explorer, Data Standards, Webinar

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

Biologics, Certara Products - Certara IQ, Modeling and Simulation, Modeling and Simulation - QSP, Publication

EANM 2026

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - QSP, Therapeutic Specialties, Conference

From Dosimetry to Dose Decisions How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Therapeutic Specialties, Webinar

Model smarter, not harder: How Phoenix Cloud puts the science back at the center of modeling

Certara Products - Phoenix, Model Informed Drug Development, Modeling and Simulation - PK/PD, Blog

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Publication

When to conduct hepatic impairment studies and when modeling may be enough

Certara Products – Simcyp, Certara Services, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Blog

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Certara Services, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Conference

Integrated mechanistic modeling approaches in oncology drug development

Biologics, Certara Products - Certara IQ, Certara Products - Simcyp, Drug Safety, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - QSP, Webinar

AI, HTA, and the future of access: Inside the 12th annual Kraków HTA symposium

Market Access, Modeling and Simulation, Blog

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Certara Services, Clinical Pharmacology, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Blog

1
2
3
……
70
›

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

早期临床

最新资源

Assessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification

Important drug development questions that model-based meta-analysis answers

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

Model smarter, not harder: How Phoenix Cloud puts the science back at the center of modeling

精选资源

Model smarter, not harder: How Phoenix Cloud puts the science back at the center of modeling

Upcoming early clinical webinars

Unlock the Power of SEND Data: From FDA Compliance to Global Regulatory Readiness for Preclinical data [Korean Webinar]

Explore Smarter, Faster PK/PD with Phoenix

Subcutaneous absorption model

Latest early clinical blogs

药物开发中 PK/PD 建模的机器学习

美国 FDA MIDD 配对试点计划如何帮助赞助商

揭秘临床 DDI 研究：精准测量代谢产物

为何 FDA 批准 omaveloxolone 用于治疗弗里德赖希共济失调症意义重大

细胞疗法开发的主要考虑因素

降低药物开发风险：早期开发中的关键化学、制造和控制（CMC）及基于生理的药代动力学（PBPK）方法

在以下活动中与我们的专家会面

Simcyp 专题研讨会：DDI（复杂药物相互作用的预测与评估）日本

Simcyp 线下研讨会：PBPK 建模在生物药剂学中的应用 — 日本

Phoenix Pharmacometrics Day – Korea

All early clinical resources

Important drug development questions that model-based meta-analysis answers

Unlock the Power of SEND Data: From FDA Compliance to Global Regulatory Readiness for Preclinical data [Korean Webinar]

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

EANM 2026

From Dosimetry to Dose Decisions How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development

Model smarter, not harder: How Phoenix Cloud puts the science back at the center of modeling

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

When to conduct hepatic impairment studies and when modeling may be enough

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Integrated mechanistic modeling approaches in oncology drug development

AI, HTA, and the future of access: Inside the 12th annual Kraków HTA symposium

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

订阅时事通讯

快捷链接

解决方案

联系我们